1736 related articles for article (PubMed ID: 9030781)
1. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinases by purine analogues.
Veselý J; Havlicek L; Strnad M; Blow JJ; Donella-Deana A; Pinna L; Letham DS; Kato J; Detivaud L; Leclerc S
Eur J Biochem; 1994 Sep; 224(2):771-86. PubMed ID: 7925396
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
6. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.
Abraham RT; Acquarone M; Andersen A; Asensi A; Bellé R; Berger F; Bergounioux C; Brunn G; Buquet-Fagot C; Fagot D
Biol Cell; 1995; 83(2-3):105-20. PubMed ID: 7549905
[TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
[TBL] [Abstract][Full Text] [Related]
9. ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells.
Zhang W; Lee JC; Kumar S; Gowen M
J Bone Miner Res; 1999 Apr; 14(4):528-35. PubMed ID: 10234573
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of 6-DMAP, olomoucine and roscovitine on Xenopus oocytes and eggs.
Flament S; Bodart JF; Bertout M; Browaeys E; Rousseau A; Vilain JP
Zygote; 2000 Feb; 8(1):3-14. PubMed ID: 10840869
[TBL] [Abstract][Full Text] [Related]
11. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
Iseki H; Ko TC; Xue XY; Seapan A; Townsend CM
J Gastrointest Surg; 1998; 2(1):36-43. PubMed ID: 9841966
[TBL] [Abstract][Full Text] [Related]
12. Cdc2 and Cdk2 kinase activated by transforming growth factor-beta1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells.
Choi KS; Eom YW; Kang Y; Ha MJ; Rhee H; Yoon JW; Kim SJ
J Biol Chem; 1999 Nov; 274(45):31775-83. PubMed ID: 10542199
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
14. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.
Oh CH; Lee SC; Lee KS; Woo ER; Hong CY; Yang BS; Baek DJ; Cho JH
Arch Pharm (Weinheim); 1999 Jun; 332(6):187-90. PubMed ID: 10399486
[TBL] [Abstract][Full Text] [Related]
16. Cdk2 activity is dispensable for the onset of DNA replication during the first mitotic cycles of the sea urchin early embryo.
Moreau JL; Marques F; Barakat A; Schatt P; Lozano JC; Peaucellier G; Picard A; Genevière AM
Dev Biol; 1998 Aug; 200(2):182-97. PubMed ID: 9705226
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
18. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase.
Kitagawa M; Okabe T; Ogino H; Matsumoto H; Suzuki-Takahashi I; Kokubo T; Higashi H; Saitoh S; Taya Y; Yasuda H
Oncogene; 1993 Sep; 8(9):2425-32. PubMed ID: 8395680
[TBL] [Abstract][Full Text] [Related]
19. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.
Havlícek L; Hanus J; Veselý J; Leclerc S; Meijer L; Shaw G; Strnad M
J Med Chem; 1997 Feb; 40(4):408-12. PubMed ID: 9046330
[TBL] [Abstract][Full Text] [Related]
20. Evidence that Fas-induced apoptosis leads to S phase arrest.
N'cho M; Brahmi Z
Hum Immunol; 2001 Apr; 62(4):310-9. PubMed ID: 11295463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
